Gilead Sciences, Inc. $GILD Stock Holdings Lifted by Tidal Investments LLC

Tidal Investments LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.8% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 545,861 shares of the biopharmaceutical company’s stock after buying an additional 44,021 shares during the period. Tidal Investments LLC’s holdings in Gilead Sciences were worth $68,964,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. MCF Advisors LLC raised its position in shares of Gilead Sciences by 7.6% during the 2nd quarter. MCF Advisors LLC now owns 21,492 shares of the biopharmaceutical company’s stock worth $2,715,000 after purchasing an additional 1,518 shares during the period. National Pension Service boosted its position in Gilead Sciences by 1.4% during the 2nd quarter. National Pension Service now owns 3,062,393 shares of the biopharmaceutical company’s stock valued at $386,903,000 after purchasing an additional 40,925 shares during the period. Engineers Gate Manager LP acquired a new position in Gilead Sciences during the 2nd quarter valued at approximately $14,262,000. Cidel Asset Management Inc. grew its stake in Gilead Sciences by 2.1% during the 2nd quarter. Cidel Asset Management Inc. now owns 8,666 shares of the biopharmaceutical company’s stock worth $1,095,000 after buying an additional 180 shares during the last quarter. Finally, Capital Analysts LLC increased its position in Gilead Sciences by 1.9% in the second quarter. Capital Analysts LLC now owns 6,923 shares of the biopharmaceutical company’s stock worth $875,000 after buying an additional 131 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ GILD opened at $145.65 on Thursday. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29. The firm has a market capitalization of $180.60 billion, a PE ratio of -54.55 and a beta of 0.33. The company’s 50 day simple moving average is $137.96 and its 200 day simple moving average is $136.28. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. During the same period last year, the company posted $2.01 EPS. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post -0.48 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s payout ratio is presently -122.85%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on GILD shares. Royal Bank Of Canada boosted their price target on shares of Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a report on Wednesday, August 5th. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the company from $133.00 to $155.00 in a research note on Monday, July 6th. Wall Street Zen cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Saturday, September 5th. Leerink Partners cut Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Finally, Barclays reduced their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $158.04.

Insider Activity

In other Gilead Sciences news, CFO Andrew Dickinson sold 3,000 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $138.36, for a total value of $415,080.00. Following the completion of the sale, the chief financial officer directly owned 165,646 shares of the company’s stock, valued at approximately $22,918,780.56. This represents a 1.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the transaction, the chief executive officer owned 592,133 shares of the company’s stock, valued at approximately $77,160,851.23. This trade represents a 2.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 105,000 shares of company stock valued at $14,495,820 over the last quarter. Insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.